TKTheresa Kehoe

Theresa Kehoe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Theresa Kehoe has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience

    by Kimberly A. Smith, Yin Huang, Theresa Kehoe, Stefanie Kraus, Mark Levenson, Jie Li, Kristen Miller, Ann Punnoose, Donna R. Rivera, Yueqin Zhao, et al.

    Advances in the availability and analysis of real‐world data (RWD) have enabled the generation of robust real‐world evidence (RWE) to support regulatory decision making by the US Food and Drug Administration. Realizing the full potential of RWE in a regulatory environment requires cross‐discipline expertise and collaboration to increase confidence in RWE‐based approaches. The FDA's Advancing RWE Program was established to address this need by providing a new option for regulatory interactions on RWE‐based approaches.


  • Regulatory aspects of the development of drugs for metabolic bone diseases – FDA and EMA perspective

    by Theresa Kehoe, Eberhard Blind, Heidi Janssen

    Regulation of medicines involves complex scientific and public health policies which are reflected in the regulatory approaches used by the European Medicines Agency and the United States Food and Drug Administration for the approval of products developed for metabolic bone diseases. For osteoporosis therapies, utilized by many patients, approaches and existing guidance for product development of both Agencies are similar; confirmatory studies for the approval of osteoporosis products can rely on well‐defined efficacy outcome parameters. Therapeutics for rare bone diseases, a rapidly expanding area, often require an individualized regulatory approach. This review outlines key aspects of these regulatory approaches applied by the two Agencies for products for metabolic bone diseases.


  • Bone quality: A perspective from the food and drug administration

    by Theresa Kehoe

    Osteoporosis, a disease of compromised bone strength, is a leading cause of fracture, morbidity, and mortality. The past 10 years have resulted in the development of new pharmacologic therapies for the treatment of this disease. Most of these agents have been approved for the treatment of osteoporosis based on placebo-controlled fracture trials. However, recent ethical concerns regarding placebo-controlled trials threaten to derail the development of new, possibly better, treatment options. Novel noninvasive imaging technologies may offer greater insight into the pathophysiology and biomechanics of osteoporosis and fracture. Because of these advances, many hope to find a new biomarker that will predict fracture risk better than the current bone density measurements and that ultimately will replace fracture as the primary endpoint for osteoporosis drug registration trials. This paper discusses the perspective of a Food and Drug Administration reviewer regarding the role of surrogate markers as they relate to the quest for new, safe and efficacious treatments for osteoporosis.